medRxiv preprint doi: https://doi.org/10.1101/2024.07.25.24309825; this version posted July 26, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.
A central research portal for mining pancreatic clinical and molecular datasets and accessing biobanked samples.
J. Oscanoa^{1,a}, H Ross-Adams^{1,a}, Abu Z M Dayem Ullah^{1,2}, TS Kolvekar^{1,2}, L Sivapalan¹, E Gadaleta¹, GJ Thorn¹, M Abdollahyan¹, A Imrali², A Saad^{2, 4}, R Roberts², C Hughes²,

- 6 PCRFTB, HM Kocher^{2, 3, 4}, C Chelala^{1,2, *}
- 7
- 8 ¹Centre for Cancer Biomarkers and Biotherapeutics, Barts Cancer Institute, Queen Mary
- 9 University London, UK, EC1M 6BQ
- 10 ² Pancreatic Cancer Research Fund Tissue Bank, Centre for Tumour Biology, Barts Cancer
- 11 Institute, Queen Mary University London, UK, EC1M 6BQ
- ³ Centre for Tumour Biology, Barts Cancer Institute, Queen Mary University London, UK,
- 13 EC1M 6BQ
- ⁴ Barts and the London HPB Centre, The Royal London Hospital, Barts Health NHS Trust,
- 15 Whitechapel, London E1 1BB
- 16
- 17 *Corresponding Author: Prof C Chelala, <u>c.chelala@qmul.ac.uk</u>
- 18 ^aThese authors contributed equally.
- 19
- 20 PCRFTB: Mo Abu Hilal (Southampton), Bilal Al Sarireh (Swansea), Somaiah Aroori
- 21 (Plymouth), Ali Arshad (Southampton), Satyajit Bhattacharya (The London Clinic, London),
- 22 Brian Davidson (Royal Free, London), John Isherwood (Leicester), Deep Malde (Leicester),
- 23 Stuart Robinson (Newcastle), Zahir Soonawalla (Oxford).
- 24
- 25
- 26
- 27
- 28

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

30 Abstract

31 The Pancreatic Expression Database (PED) is a powerful resource dedicated to the mining 32 and analysis of pancreatic -omics datasets. Here, we demonstrate the biological 33 interpretations that are possible because of vital updates that have transformed PED into a 34 dynamic analytics hub accommodating an extensive range of publicly available datasets. 35 PED now hosts clinical and molecular datasets from four primary sources (Cancer Genome 36 Atlas, International Cancer Genome Consortium, Cancer Cell Line Encyclopaedia and 37 Genomics Evidence Neoplasia Information Exchange) that together form the foundation of 38 omics profiling of pancreatic malignancies and related lesions (n=7,760 specimens). Several 39 user-friendly analytical tools to explore and integrate the molecular data derived from these primary specimens and cell lines are now available. Crucially, PED is integrated as the data 40 access point for Pancreatic Cancer Research Fund Tissue Bank - the only national 41 pancreatic cancer biobank in the UK. This will pioneer a new era of biobanking to promote 42 43 collaborative studies and effective sharing of multi-modal molecular, histopathology and 44 imaging data from biobank samples (>60,000 specimens from >3,400 cases and controls; 45 2,037 H&E images from 349 donors) and accelerate validation of in silico findings in patient-46 derived material. These updates place PED at the analytical forefront of pancreatic 47 biomarker-based research, providing the user community with a distinct resource to facilitate 48 hypothesis-testing on public data, validate novel research findings, and access curated, 49 high-quality patient tissues for translational research. To demonstrate the practical utility of 50 PED, we investigate somatic variants associated with established transcriptomic subtypes 51 and disease prognosis: several patient-specific variants are clinically actionable and may be 52 leveraged for precision medicine.

53

54 Introduction

Pancreatic ductal adenocarcinoma (PDAC) is predicted to become the second leading cause of cancer-related mortality worldwide before 2040¹. It has dismal 5-year survival rates of 3-15%^{1,2}, largely due to late disease detection and few effective treatment options. Alarmingly, the incidence of early-onset pancreatic cancer is also increasing, in contrast to most other solid tumours³. Better tools for patient stratification and treatment response are thus

essential to improve survival outcomes. However, the pancreatic cancer research
community is relatively small – investigators tend to develop bespoke collections of samples
that may be unusable beyond the breadth and scope of their ethical approval and storage
conditions. Sample collection protocols also vary widely, further limiting the translation of
derived results to clinical benefits.

65

66 Most existing biomarkers for monitoring treatment or assessing prognosis are not based on the molecular attributes of PDAC tumours and have shown limited sensitivity and/or 67 specificity in prospective settings⁴. Numerous studies into the genomic and transcriptomic 68 determinants of tumour development and progression are available, but their findings are 69 70 dispersed across multiple resources, and can be difficult to access and translate into 71 meaningful survival or treatment benefits for patients by those without computational 72 expertise. This highlights the pressing need for simplified, integrated data mining and 73 analysis tools to improve accessibility to clinical and molecular information from disparate 74 sources and enable laboratory and clinical researchers to easily and effectively cross-query 75 large multi-omics datasets, to fuel new discoveries in pancreatic diseases.

76

77 Here, we present the latest release of the Pancreatic Expression Database (PED), an 78 intuitive, online portal that links numerous multi-modal datasets to an active biobank where 79 users can both validate their findings, and/or apply for samples to confirm *in silico* findings. 80 To remain abreast of the evolving nature of integrative multi-omics workflows and in 81 response to user feedback, we have made vital new updates to PED's Analytics Hub, 82 broadened the range of datasets available and placed this essential resource at the centre 83 of the established framework for PED (Table 1). We have also integrated PED as the major 84 bioinformatics platform of the UK's national Pancreatic Cancer Research Fund Tissue Bank 85 (PCRFTB), to facilitate investigative biomarker-based research and data sharing between 86 clinicians and scientists. This is powered by a customised version of SNPNexus, a versatile platform for the functional annotation of known and novel sequence variation⁵, designed to 87 88 reduce the analytical burden associated with large-scale genomic datasets and facilitate the 89 straightforward identification of biologically and clinically relevant genetic variants in patients.

90

91 The PCRFTB is the world's first national pancreas tissue bank and has been collecting 92 blood, urine, saliva and solid tissue samples from patients recruited at nine participating 93 centres across the UK NHS since 2015, making it a valuable resource for translational 94 research. Tissues are available from patients with pancreatic and hepatobiliary diseases, 95 including resectable and unresectable cancer. Blood, urine and saliva samples from 96 patients, their first-degree relatives and other healthy volunteers are also available, as well 97 as cancer organoids and cancer-associated fibroblasts. (Figure 1). These are accompanied 98 by extensive, verified clinical, histological and imaging data that is continually updated -99 median 300 data points per visit, with some donors providing longitudinal samples at multiple 100 visits throughout their treatment journey. Best practice and ongoing technical research 101 ensures available biological materials are of high quality, to support reliable and reproducible 102 results^{6,7} In addition to samples, digitised radiological images are available for 171 patients 103 with malignant, pre-malignant and benign pancreatic diagnoses, and 2,037 H&E images 104 from 349 donors are also currently available.

105

The PCRFTB is further supported by a Data Return policy to maximise the use of available 106 107 samples by linking each patient/donor with an enriched 'digital fingerprint' encompassing 108 molecular, transcriptomic, proteomic, imaging and longitudinal clinical data. All donors 109 provide written, informed consent, and all samples are collected, processed and stored at 110 each of the participating centres (Barts, Leicester, Swansea, Oxford, Royal Free (London), 111 Southampton, Newcastle, Plymouth, The London Clinic) under one Research Ethics Committee reference (13/SC/0593, renewed 18/SC/0629, renewed 23/SC/0282) and using 112 standardised protocols, quality assurance and quality control policies ensuring consistency 113 114 across the collection.

115

Via PED, researchers can directly query and apply to PCRFTB for samples, specimens
and/or imaging data that match user-determined criteria. A link to the PCRFTB Tissue
Request System allows users to submit Expressions of Interest directly to the Tissue Bank
using an online application form.

120

121 By providing a dynamic hub for the analysis of publicly available pancreatic datasets and

122 ongoing research data generated from biobanked samples, PED allows researchers to

123 access a broad range of pancreas-specific molecular information freely and quickly. The

124 flexibility of this hub allows molecular alterations with biological and clinical relevance to be

- identified and prioritised for downstream validation.
- 126

127 The Analytics Hub

128 We have updated the web-based Analytics Hub to include a broad range of pancreas-

129 related, publicly available -omics datasets, together with expanded analytical features and

130 visualisation options (Table 1), based on feedback from our diverse international user

131 community.

132

133 Publicly available data sources

134 Building on the 2018 release⁸, the newly formed analytics hub now hosts publicly available 135 clinical and molecular datasets from four core sources: The Cancer Genome Atlas (TCGA)⁹ whole exome sequencing (WES) data, updated to filter specifically for adenocarcinoma 136 samples vs others; the Cancer Cell Line Encyclopaedia (CCLE)¹⁰, updated to include 137 somatic mutation and mRNA expression data for the complete set of 60 pancreas cell lines 138 139 from primary and metastatic tumours; the Genomics Evidence Neoplasia Information Exchange (GENIE)¹¹ v13.0, updated to include simple somatic mutations and clinical data 140 141 from the *complete* set of 6,633 patients with pancreatic cancer of any type; and the now archived complete International Cancer Genome Consortium (ICGC)^{12,13} dataset, including 142 143 whole genome and RNA sequencing data from both adenocarcinoma (PACA-AU; PACA-CA) 144 and neuro/endocrine tissues (PAEN-IT; PAEN-AU). These sources host data generated by 145 both national and international consortia efforts to sequence and analyse cancer genomes 146 and biology, including pancreatic malignancies. Analysed and guality-controlled data files 147 were downloaded from the respective sources and used without further processing. PED 148 2024 uses the most recent data releases, including linked clinical data when available.

150 Advanced filtering of public datasets

151 Public datasets may be queried according to the clinical characteristics of each study cohort 152 (Figure 2A). Filtering options have been selected based on relevance to disease development 153 and pathogenesis, and the depth of annotation provided in available clinical data for each 154 cohort. Implemented filters are accompanied by dedicated visualizations of clinical summaries 155 for each respective study cohort (Figure 2B). These include filters based on patient-related 156 factors (cancer type, sex, age, diabetes, family history, ethnicity, survival; Figure 2C), and 157 tumour characteristics (stage, grade, KRAS somatic mutation status) (Figure 2D), which allow 158 for trends in data to be clearly observed: e.g. survival beyond 3 years is very low for PDAC 159 compared to neuroendocrine tumours (Figure 2B). Crucially, it is possible to filter each dataset by diagnosis, allowing researchers to focus on different pancreatic lesions individually (e.g. 160 IPMN, ductal adenocarcinoma, neuroendocrine, adenosquamous, mucinous) that have 161 different molecular alterations and clinical prospects, since using unstratified sample sets has 162 been shown to yield unreliable results.^{14,15} 163

164

165 Characterising the genomic characteristics of established PDAC molecular subtypes

PED facilitates the stratification and analysis of TCGA and ICGC cohorts according to their molecular subtype classifications, as determined by hallmark transcriptomic^{16–18} and genomic (ICGC only)¹⁹ studies, and recent histopathology-based artificial intelligence (AI) predictions in matched TCGA samples²⁰(Figure 2E). We demonstrate the implementation of this clinically useful feature below.

171

Collisson et al. (2011) originally identified 3 subclasses of PDAC tumours with different
clinical outcomes and treatment responses, termed *quasi-mesenchymal* (QM) (worst
prognosis), *classical* (best prognosis) and *exocrine-like*, using hybridisation array-based
mRNA expression data from primary untreated resected PDAC¹⁶. Next, Moffitt et al (2015)
analysed bulk tumour tissues from treatment-naïve primary resected PDAC tumours using
virtual microdissection to exclude transcripts native to the normal pancreas and the tumour
microenvironment, and reported 2 distinct tumour subtypes (*basal* and *classical*) as well as 2

classifications based on peritumoural stromal tissues (activated and normal)¹⁷. Basal 179 180 subtype tumours were associated with a poorer overall patient survival compared to classical 181 tumours, which overlapped significantly with the Collisson *classical* subtype. Subsequently, 182 Bailey et al. performed RNA-sequencing of bulk primary untreated resected tumour tissues 183 from 328 PDAC tumours and resolved four stable tumour classes (squamous, pancreatic 184 progenitor, immunogenic and aberrantly differentiated endocrine exocrine (ADEX)), each governed through the differential expression of transcription factors and their targets 185 involved in lineage specification during pancreatic development¹⁸. Squamous subtype 186 tumours overlapped with previous basal (Moffitt) and QM (Collisson) classifications and were 187 188 associated with the poorest overall prognosis in patients. Recent investigations of these 189 proposed classifications have corroborated the presence of 2 overarching transcriptomic 190 subtypes of PDAC tumours comprising basal-like/squamous and classical/progenitor that 191 have shown relevance for defining survival outcomes in patients, with remaining subtypes 192 (exocrine-like, ADEX) shown to have confounding associations with poor tumour 193 cellularity^{21,22}. Most recently, Saillard et al (2023) used an artificial intelligence model trained and validated on 5 independent surgical and biopsy cohorts with RNAseg and 194 195 histology data (n=598), including n=126 TCGA samples to further refine these tumour subtypes²⁰. This approach recapitulated the known *basal/classical*¹⁷ tumour subtypes at the 196 197 whole H&E slide level but detected variable proportions of basal cells in samples previously 198 categorised as classical subtype when slides were analysed at 112 µm tile size level. This 199 changed survival outcomes in 39% of cases classed as *classical* subtype by bulk RNAseq 200 analysis, with the impact apparently proportional to the percentage basal cell content.²⁰ 201

At the DNA level, whole genome sequencing (WGS) and copy number variant (CNV) analysis performed on 100 treatment-naïve, macro-dissected PDAC tissues (ICGC Australia) identified four disease subtypes with distinct patterns of structural variation (*scattered, locally rearranged, stable, unstable*) and clinical utility, with *unstable* subtype characterised by a very high degree of genomic instability throughout the genome and encompassing defects in DNA damage repair (DDR) pathways that confer susceptibility to PARP inhibition (PARPi) and/or platinum chemotherapies¹⁹.

209

210 Application of subtype-specific filtering criteria in study cohorts

211 Subtype-specific characteristics can be explored using the TCGA (n=185) and newly added 212 ICGC Australia (PACA-AU, n=461) and Canada (PACA-CA, n=317) pancreatic cancer cohorts. Molecular subtype classifications according to Collisson¹⁶, Moffitt¹⁷, Bailey¹⁸ and/or 213 Saillard²⁰ are available for n=134 of the 156 confirmed PDAC patients included in the TCGA 214 215 cohort²¹. Alternatively, ICGC-AU cohorts can be analysed according to the subtype classifications proposed by Bailey et al (2016)¹⁸ (n=95 patients total; 81 PDAC) and/or 216 Waddell et al (2015)(n=86 patients total; 85 PDAC).¹⁹ Given the prognostic relevance of 217 218 these transcriptomic subtypes, here we explore the associated genomic features of TCGA 219 PDAC tumours classed unanimously as either classical/progenitor (n=27) or QM/basal-220 like/squamous (n=16) by all three subtyping systems (Collisson/Moffit/Bailey), as an 221 example of PED Analytics Hub. 222 Subtype-specific somatic variations 223

224 Comparisons between the genomic characteristics of each TCGA subtype showed different 225 gene sets mutated in *classical* and *basal* subtypes (Figure 3A, B). This was also true for 226 PACA-AU prognostic subtypes (progenitor vs squamous) (Supplementary Figure 1A, B), but 227 with little consensus between the two cohorts (Supplementary Figure 1C). To more reliably 228 identify subtype-specific genetic variations robust to inevitable inter-study variability (e.g. tissue heterogeneity; WES vs WGS²³), we considered the union of the top 25 most 229 230 frequently mutated genes between similar prognostic groups for the two largest datasets 231 (TCGA+ICGC). This revealed a handful of common genes detected at >10% prevalence 232 (KRAS, TP53, CDKN2A, MUC16, LRP1B, AFF2, FAT4), but with most genes/variants being 233 subtype-specific (Figure 3C), consistent with (1) the early acquisition of these common 234 alterations during PDAC tumour development and (2) the molecular heterogeneity of PDAC tumours²¹. 235

236

238 Identifying treatment biomarkers

239 In silico functional analysis of all patient-specific somatic variants identified, using the most recent, freely available embedded Cancer Genome Interpreter (CGI)²⁴ analytic tool, 240 identified numerous biomarkers of response/resistance to existing clinical treatments and/or 241 242 pharmacological inhibitors (Supplementary Table S2) in various cancer contexts, including 243 multiple variants in KRAS, TP53, CDKN2A and LRP1B. Although KRAS is extensively 244 mutated across both prognostic groups, KRAS p.G12C driver variants were unique to the 245 best prognosis subtype tumours (Supplementary Table S2). This variant, rare in PDAC (<1% 246 patients)²⁵, has been shown to preferentially drive the RAF/RAL pathway, while the more common KRAS^{G12D} mutation (~30% PDAC patients) favours the PI3K/AKT pathway^{25,26}. 247 Targeted KRAS^{G12C} inhibitor sotorasib has recently received FDA approval for treatment of 248 mNSCLC²⁷, and has been shown to be safe and effective in treatment of advanced mPDAC, 249 in a Phase I/II trial in n=38 patients²⁸. Additionally, certain variants in CDKN2A (L104V, 250 251 E120*, R58*, R80*) have been linked with treatment resistance to PD1 inhibitors, and 252 treatment response to CDK4/6 inhibitors in cutaneous melanoma (CM; Supplementary Table 253 S2), highlighting the usefulness of PED in identifying potentially clinically relevant patient-254 and cancer-specific therapeutic targets. 255

256 Of the somatic variants identified, CGI oncogenic classifications (bioactivity) (Supplementary 257 Table S1), revealed several to be TIER 1 predicted driver variants, i.e. the gene activity is confirmed relevant to cancer, with mutations identified effecting oncogenic transformation. 258 259 Only one was identified in the poorest outcome patient group - a splice donor variant in central cell-cycle regulator gene ATM, and linked with response to cisplatin chemotherapy, 260 261 PARPi by olaparib, and PD1/PD-L1 inhibition in other solid tumours (Supplementary 262 Table S2). However, this variant was uncommon in the sample set (1/16). Conversely, 263 several TIER 1 oncogenic driver variants were identified in the best prognosis patient group, 264 with some associated with response/resistance to specific drugs in other solid tumours, 265 suggesting possible utility in pancreatic cancer: ARID1A (p.E1542*, p.Q1277*; responsive to EZH2, PD1, ATR & PARP inhibitors), RNF43 (W159*, responsive to porcupine inhibitor) and 266

TP53 (S166*, Y205S, D259V, M246R, S241F, L194H, N131I; resistance to CDK4/6 inhibitor
abemaciclib, cisplatin, MDM2 inhibitor; responsive to ATR inhibitor AZD6738, doxorubicin,
decitabine, gemcitabine, mitomycin C).

270

271 Results of the above detailed output are also summarised in alluvial plots, showing clinically-272 actionable targets present in selectable proportions of the filtered dataset (5%-25%) and 273 their responsiveness/resistance to available drugs (Supplementary Figure 2A, B), as well as 274 a visual summary of the number of druggable gene categories represented in the selected 275 dataset (Supplementary Figure 2C, D), that shows different clinically actionable genome 276 targets between the two prognostic groups. While the most commonly mutated genes are 277 common between prognostic subtypes (\geq 25% of patients from both groups contain similar 278 KRAS and TP53 variants), distinct biomarker/drug combinations are apparent when less 279 common variations are considered: only one other gene in the poor prognosis group was 280 identified as harbouring variants linked to (among others) responsiveness to small molecule 281 AURKA-VEGF inhibitor ilorasertib (CDKN2A R58*), whereas the better prognosis subgroup 282 is associated with 6 additional gene/biomarker candidates (RNF43, PIK3CA, ERCC4, 283 CTNNB1, CDKN2A, ARID1A), that have shown promise in treating other solid tumours. 284 Additionally, by exploring the available CCLE database of 60 pancreatic cell lines, in vitro 285 models with/without KRAS and/or TP53 variants may be identified to support downstream 286 functional studies.

287

These results demonstrate the value of PED in contextualising individual patient genetic profiles in suggesting possible treatment options, or refining research areas to pursue for more effective, stratified approaches in pancreatic cancer.

291

292 Characterising patterns of gene expression in best- and worst-outcome tumours

293 Inspecting the top 250 differentially expressed genes in both TCGA and ICGC filtered patient

subgroups confirms scant overlap between genes differentially expressed in best and worst-

295 outcome PDAC tumours. However, classical/progenitor tumours appear to have higher

296 TP53 expression compared to QM/basal/squamous tumours, consistent with its role as

297 tumour suppressor (Figure 4A) and mirrored in ICGC progenitor and squamous patient 298 subgroups¹⁸ (Supplementary Figure 3). Subtype-specific differences in expression were also 299 observed for MUC16 (encoding CA125 membrane glycoprotein) which was over-expressed in QM/basal/squamous subtype tumours, compared to classical/progenitor cases (Figure 300 301 4B). Considering all n=402 confirmed PDAC in PACA-AU (the largest single transcriptomic 302 dataset), PED shows that MUC16 over-expression is associated with significantly reduced 303 patient survival (logrank p=0.011; HR=2.23) (Figure 4C), where no association was found for 304 neuroendocrine tumours (Figure 4D). Elevated CA125 has also recently been shown to be 305 an independent prognostic marker of significantly shorter survival in n=207 resectable PDAC patients, both before and after treatment²⁹. Functionally, CA125 over-expression has been 306 307 shown to promote tumourigenesis in vitro and in vivo^{30,31}, and monoclonal antibody mAb AR9.6 has recently shown potential as a specific and effective inhibitor of CA125 and its 308 oncogenic effects in pancreatic and ovarian cancers^{31,32}. 309

310

Identifying clinically actionable genomic alterations in KRAS wild-type PDAC tumours 311 312 Several studies have explored the genetic landscape of KRAS wild-type tumours, delineating several alterations that occur frequently in the absence of mutant KRAS^{21,33–35}. In addition, 313 314 a significant enrichment for somatic aberrations that target the RAS-MAPK pathway, either upstream or downstream of KRAS, has been observed in up to one-third of KRAS wild-type 315 tumours^{21,35}, where *BRAF* alterations were prevalent and mutually exclusive with *KRAS* 316 317 mutations³⁵. However, alterations within genes that are not typically associated with RAS 318 signalling have also been widely identified across KRAS wild-type PDAC tumours, and require further investigation to determine functional relevance^{18,21}. 319

320

321 Alternative oncogenic drivers amongst KRAS wild-type PDAC tumours

We used GENIE¹¹ as the largest available resource to identify n=756 *KRAS* wild-type PDAC samples. To identify other likely molecular drivers in these tumours, predictions from CGI were analysed to evaluate the distribution of altered genes and their associated pathways. Mutations were detected across several genes previously reported to be altered in *KRAS*

wild-type PDAC cases, including *TP53* (mutated in >40% of the samples), *GNAS* and *BRAF*³⁶ (Figure 5A). *In silico* biomarker predictions also showed that *ARID1A*, *BRAF*, *CDKN2A*, *GNAS*, *PIK3CA* and *TP53* variants demonstrated therapeutic potential in
response to PARP, tyrosine kinase and VEGF inhibitors, immunotherapies and several
chemotherapies (Figure 5B).

The analysis of altered signalling pathways amongst mutated genes across *KRAS* wild-type samples revealed frequent alterations in pathways associated with MAPK signalling, P53 signalling, neurotrophin, cell cycle, wnt and apoptosis signalling, consistent with previous characterisations of core biological pathways involved in PDAC development and progression^{18,19,21,30,36}. (Figure 5C). These findings highlight the utility of PED for the prioritisation of functionally and biologically relevant variants amongst subgroups of PDAC tumours, with important implications for the characterisation of distinct molecular pathologies

and the identification of novel therapeutic opportunities.

340

Using the PED Analytics Hub, we demonstrate how our integrated high-performance visualisation and analysis tool can be used to investigate the link between genomic and transcriptomic features and phenotypes of pancreatic cancer, providing an important step in defining potential subtype-specific therapeutic vulnerabilities.

345

346 The PCRFTB Data Return Module

347 The vision of precision medicine has driven unprecedented interest into biomarker-based 348 studies (genomics, transcriptomics, proteomics) for pancreatic cancer, which are being 349 adopted across research and development from early discovery through to clinical research and trials³⁷. Fundamental to biomarker research is access to quality biospecimens and 350 351 samples that have been well annotated with clinical and molecular data⁶. Whilst many 352 biobanks have invested heavily in the IT infrastructure of sample management, most 353 platforms are facing challenges in the effective sharing of returned data to drive investigative 354 research across the pancreatic research community. A major challenge is the rise of so-355 called 'big data' from e.g. NGS and images that need to be integrated with large quantities of

primary/secondary care information and other real-world healthcare data. Traditional
biobanks are not usually set up to leverage these innovations, which have the potential to
improve patient outcomes and accelerate the development and delivery of new therapies.
PED is now the primary bioinformatics platform of the PCRFTB, providing a unique
integrated resource of biological materials and associated clinical, molecular and
radiological/imaging data.

363 In addition to providing a direct link to sample requests from the PCRFTB, the newly 364 incorporated data return module in PED hosts clinical and molecular data returned to the 365 bank from studies undertaken using PCRFTB specimens, where published findings have been made available for researchers to review and analyse prior to submitting a tissue 366 request. Studies are categorised according to the type of -omics data generated for each 367 368 project (i.e. genomic, transcriptomic or proteomic), with alternative data types (e.g. 369 summaries of staining or imaging results generated from experimental investigations) 370 classified "other", to simplify use. These classifications are presented in a summary table, 371 which also provides a description of each project and details the different sample types (i.e. 372 blood, tissues, cell lines) and cohort sizes used for each project. Users also have the option 373 view this information as clinical summary plots for each individual cohort, prior to exploring 374 available molecular data from each study.

375

Like other tissue repositories^{38,39}, PCRFTB has implemented a data return policy, where 376 377 anonymised data derived from banked samples is returned to the tissue bank on completion 378 of the study and made freely available to the research community, regardless of whether the study is ultimately published⁶. As associated sample datasets develop, more in-depth 379 integrative analyses will be possible. Under PCRFTB Data. PED lists the details of any 380 381 returned data and associated sample characteristics available for analysis, while PCRFTB 382 Research Projects links directly to the relevant published report. So far, this has further enriched the data available for banked tissue sample and/or patients, and currently includes 383 data on stromal⁴⁰, urinary miRNA⁴¹, metallomic⁴², and volatile organic compound⁴³ 384 biomarkers, proteomics (ELISA)⁴⁴, circulating tumour cells (CTCs) and xenotransplantation 385

models^{45,46}, germline and somatic mutations⁴⁷, a phase I clinical trial⁴⁸, and risk⁴⁹ and
recurrence⁵⁰ predictions incorporating electronic health record data. To date, PCRFTB has
processed 38 EoI, supported 33 research projects and 19 peer-reviewed publications.
Ultimately, each study contributes to the development of a 'digital fingerprint' for each
patient, linking multi-modal data with longitudinal clinical information.

391

PED Analytics Hub is the web-based portal through which this enriched dataset can be accessed and compared with large scale pancreatic -omics data, with the unique benefit of also providing access to additional patient samples (*via* PCRFTB) for subsequent validation of molecular alterations with clinical potential. Here, we demonstrate the added value of tissue banking to precision cancer medicine, to translate research findings into prognostic and therapeutic tools using well-annotated curated tissues and associated clinical data.

398

399 Discussion

400 A rapid expansion in high-throughput genomic and transcriptomic profiling of pancreatic 401 diseases necessitates the development of sophisticated yet user-friendly analytics hubs to 402 host the growing compendium of molecular and clinical datasets and enable integrated 403 mining and analysis of available results. The updated PED now supports a range of data 404 modalities to enable users across the diverse international pancreatic research community to identify and investigate trends in molecular data across disparate cohorts of patients, 405 406 samples and cell lines easily and effectively. PED now provides an unprecedented 407 opportunity to characterise distinct variations in both tumour mutation landscapes and gene 408 expression profiles that are associated with prognostic molecular subtypes. Candidate 409 tumour drivers and biomarkers predictive of response to existing and novel clinical 410 treatments can be identified and visualized, allowing suitable targets for downstream 411 validation and pharmacological testing to be prioritised without the need for laborious data 412 retrieval or processing tasks. Furthermore, PED is the gateway to a national tissue bank 413 repository of >60,000 samples from >3,400 patients and a growing repository of digitised 414 radiological and H&E images, that researchers can access independently and apply for 415 donor samples that match with their research question. The selection of samples is

416 significantly improved by the availability of high-quality clinical data, curated and maintained

417 by PCRFTB.

- 418
- 419 These major updates to the PED infrastructure are further underpinned by its recent
- 420 adoption as the bioinformatics platform of the PCRFTB, pioneering a new generation in
- 421 biobanking to support effective data sharing and promote collaborative studies,
- 422 democratizing access to complex cancer genomics. By harmonising PCRFTB samples with
- 423 clinical and molecular information from datasets returned to the biobank, PED provides an
- 424 essential platform to support translational pancreatic research and fuel discoveries that can
- 425 manifest clinically meaningful benefits for patients. PCRFTB recently launched
- 426 internationally (<u>https://www.pcrf.org.uk/news/tissue-bank-launches-internationally/</u>),
- 427 improving opportunities for high-quality research into earlier diagnosis and treatment of
- 428 pancreatic cancer. As -omics driven research continues to drive efforts to advance the
- 429 characterisation of pancreatic diseases, PED's design supports the ongoing data analysis,
- 430 integration and visualisation needs of the growing research community.
- 431
- 432
- 433
- 434
- 435
- 436
- 437
- 438
- 439
- 440
- 441
- 442
- 443
- 444
- 445

446 Table 1. Summary of the 2024 updates to PED

Features	2018 release ⁸	2024 release
The PED Analytics Hub		
Publicly available data sources (pancreas-specific)		
PubMed ^a	Х	
TCGA ^b	Х	х
ICGC		Х
GENIE°	Х	х
CCLE ^d	Х	Х
Analytical features		
Principal components analysis	Х	Х
Gene expression profiles	Х	Х
Correlation analyses	Х	Х
Gene networks	Х	х
Survival analyses ^e	Х	х
Variant identification	Х	Х
Somatic gene interactions	Х	Х
Reactome & oncogenic pathway analyses		х
Improved clinical annotations to visualize & query publicly available datasets		x
MAFtools genomic analyses and summary visualisations		Х
Tumour mutational burden		Х
Clinically actionable genes/proteins & associated drugs		Х
Cohort comparison by clinical/molecular feature		Х
Gene intersections between filtered datasets		х
The PCRFTB Data Module		
Data return module to host both -omics and experimental datasets		Х
Integrated primary/secondary care clinical data		Х
Apply for samples		Х

447

448

- 450 ^a Less-used literature mining module
- 451 ^b Updated to include essential filters based on cancer subtype
- 452 ° Expanded from 445 adenocarcinoma or neuroendocrine tumours to full set of 6,633
- 453 pancreatic cancers of all types, with additional clinical and molecular information.
- ^dSomatic variant dataset; now expanded to include the full set of 60 primary and metastatic
- 455 tumour derived cell lines.
- ^e Expanded to include analyses based on mutational status and mRNA level

495 References

496

497 1. Siegel, R. L., Miller, K. D. & Jemal, A. Cancer statistics, 2020. CA Cancer J Clin 70, 7–30 498 (2020). 499 Pereira, S. P. et al. Early detection of pancreatic cancer. Lancet Gastroenterol Hepatol 2. 500 5, 698-710 (2020). 501 3. Abboud, Y. et al. Increasing Pancreatic Cancer Incidence in Young Women in the. 502 *Gastroenterology* 1–12 (2023) doi:10.1053/j.gastro.2023.01.022. 503 4. Brezgyte, G., Shah, V., Jach, D. & Crnogorac-jurcevic, T. Non-invasive biomarkers for 504 earlier detection of pancreatic cancer—a comprehensive review. Cancers (Basel) 13, 505 1-25 (2021). 506 5. Oscanoa, J. et al. SNPnexus: A web server for functional annotation of human 507 genome sequence variation (2020 update). Nucleic Acids Res 48, W185–W192 (2020). 508 6. Balarajah, V. et al. Pancreatic cancer tissue banks: where are we heading? Future 509 Oncology 12, 2661–2663 (2016). 510 7. Imrali, A. et al. Validation of a Novel, Flash-Freezing Method: Aluminum Platform. 511 Current Protocols in Essential Laboratory Techniques 21, 1–17 (2020). 512 8. Marzec, J. et al. The Pancreatic Expression Database: 2018 update. Nucleic Acids Res 513 **46**, D1107–D1110 (2018). 514 Weinstein, J. N. et al. The Cancer Genome Atlas Pan-Cancer analysis project. Nat 9. 515 Genet 45, 1113-1120 (2013). 516 Barretina, J. et al. The Cancer Cell Line Encyclopedia enables predictive modelling of 10. 517 anticancer drug sensitivity. Nature 483, 603-607 (2012). 518 Sweeney, S. M. et al. AACR project genie: Powering precision medicine through an 11. 519 international consortium. Cancer Discov 7, 818-831 (2017). 520 Zhang, J. et al. International Cancer Genome Consortium Data Portal-a one-stop shop 12. 521 for cancer genomics data. Database (Oxford) 2011, bar026 (2011). 522 13. Zhang, J. et al. The International Cancer Genome Consortium Data Portal. Nat 523 Biotechnol 37, 367-369 (2019). 524 14. Peran, I., Madhavan, S., Byers, S. W. & McCoy, M. D. Curation of the pancreatic ductal 525 adenocarcinoma subset of the cancer genome atlas is essential for accurate 526 conclusions about survival-related molecular mechanisms. Clinical Cancer Research 527 24, 3813-3819 (2018). 528 15. Nicolle, R. et al. Prognostic biomarkers in pancreatic cancer: Avoiding errata when 529 using the TCGA dataset. Cancers (Basel) 11, 1–10 (2019). 530 16. Collisson, E. A. et al. Subtypes of pancreatic ductal adenocarcinoma and their 531 differing responses to therapy. Nat Med 17, 500–503 (2011). 532 Moffitt, R. A. et al. Virtual microdissection identifies distinct tumor- and stroma-17. 533 specific subtypes of pancreatic ductal adenocarcinoma. Nat Genet 47, 1168–1178 534 (2015). 535 Bailey, P. et al. Genomic analyses identify molecular subtypes of pancreatic cancer. 18. 536 Nature 531, 47-52 (2016). 537 Waddell, N. N. N. et al. Whole genomes redefine the mutational landscape of 19. 538 pancreatic cancer. Nature 518, 495-501 (2015). 539 20. Saillard, C. et al. Pacpaint: a histology-based deep learning model uncovers the 540 extensive intratumor molecular heterogeneity of pancreatic adenocarcinoma. Nat 541 Commun 14, (2023). 542 21. Raphael, B. J. et al. Integrated Genomic Characterization of Pancreatic Ductal 543 Adenocarcinoma. Cancer Cell 32, 185-203.e13 (2017).

544 22. Sinkala, M., Mulder, N. & Martin, D. Machine Learning and Network Analyses Reveal 545 Disease Subtypes of Pancreatic Cancer and their Molecular Characteristics. Sci Rep 10, 546 1212 (2020). 547 23. Ellrott, K. et al. Scalable Open Science Approach for Mutation Calling of Tumor 548 Exomes Using Multiple Genomic Pipelines. Cell Syst 6, 271-281.e7 (2018). 549 Tamborero, D. et al. Cancer Genome Interpreter annotates the biological and clinical 24. 550 relevance of tumor alterations. Genome Med 10, 25 (2018). 551 Kwan, A. K., Piazza, G. A., Keeton, A. B. & Leite, C. A. The path to the clinic: a 25. 552 comprehensive review on direct KRASG12C inhibitors. Journal of Experimental and 553 Clinical Cancer Research 41, (2022). 554 Ihle, N. T. et al. Effect of KRAS oncogene substitutions on protein behavior: 26. 555 Implications for signaling and clinical outcome. J Natl Cancer Inst 104, 228–239 556 (2012). 557 27. Nakajima, E. C. et al. FDA Approval Summary: Sotorasib for KRAS G12C-Mutated 558 Metastatic NSCLC. Clinical Cancer Research 28, 1482–1486 (2022). 559 28. Strickler, J. H. et al. Sotorasib in KRAS p.G12C-Mutated Advanced Pancreatic Cancer . 560 New England Journal of Medicine 388, 33–43 (2023). 561 29. Napoli, N. et al. Ca 125 is an independent prognostic marker in resected pancreatic 562 cancer of the head of the pancreas. Updates Surg 75, 1481–1496 (2023). 563 30. Qi, Z. H. et al. RIPK4/PEBP1 axis promotes pancreatic cancer cell migration and 564 invasion by activating RAF1/MEK/ERK signaling. Int J Oncol 52, 1105–1116 (2018). 565 31. Thomas, D. et al. Isoforms of MUC16 activate oncogenic signaling through EGF 566 receptors to enhance the progression of pancreatic cancer. Molecular Therapy 29, 567 1557-1571 (2021). 568 32. Sharma, S. K. et al. ImmunoPET of Ovarian and Pancreatic Cancer with AR9.6, a Novel 569 MUC16-Targeted Therapeutic Antibody. Clinical Cancer Research 28, 948–959 (2022). 570 33. Heining, C. et al. NRG1 Fusions in KRAS Wild-Type Pancreatic Cancer. Cancer Discov 8, 571 1087-1095 (2018). 572 34. Luchini, C. et al. KRAS wild-type pancreatic ductal adenocarcinoma: molecular pathology and therapeutic opportunities. Journal of Experimental & Clinical Cancer 573 574 Research 39, 227 (2020). 575 Singhi, A. D. et al. Real-Time Targeted Genome Profile Analysis of Pancreatic Ductal 35. 576 Adenocarcinomas Identifies Genetic Alterations That Might Be Targeted With Existing 577 Drugs or Used as Biomarkers. Gastroenterology 156, 2242-2253.e4 (2019). 578 36. Philip, P. A. et al. Molecular Characterization of KRAS Wild-type Tumors in Patients 579 with Pancreatic Adenocarcinoma. Clinical Cancer Research 28, 2704–2714 (2022). 580 37. Herbst, B. & Zheng, L. Precision medicine in pancreatic cancer: treating every patient 581 as an exception. Lancet Gastroenterol Hepatol 4, 805-810 (2019). 582 38. Gadaleta, E., Pirrò, S., Dayem Ullah, A. Z., Marzec, J. & Chelala, C. BCNTB 583 bioinformatics: The next evolutionary step in the bioinformatics of breast cancer 584 tissue banking. Nucleic Acids Res 46, D1055–D1061 (2018). 585 39. Speirs, V. Quality Considerations When Using Tissue Samples for Biomarker Studies in 586 Cancer Research. Biomark Insights 16, (2021). 587 40. Goulart, M. R. et al. Pentraxin 3 is a stromally-derived biomarker for detection of 588 pancreatic ductal adenocarcinoma. NPJ Precis Oncol 5, (2021). 589 41. Debernardi, S. et al. Noninvasive urinary miRNA biomarkers for early detection of 590 pancreatic adenocarcinoma. Am J Cancer Res 5, 3455-3466 (2015).

591 592	42.	Schilling, K. <i>et al.</i> Urine metallomics signature as an indicator of pancreatic cancer. <i>Metallomics</i> 12 , 752–757 (2020).
593	43.	Daulton, E. <i>et al.</i> Volatile organic compounds (VOCs) for the non-invasive detection of
594	10.	pancreatic cancer from urine. <i>Talanta</i> 221 , (2021).
595	44.	Debernardi, S. <i>et al.</i> A combination of urinary biomarker panel and PancRISK score for
596	44.	earlier detection of pancreatic cancer: A case-control study. <i>PLoS Med</i> 17 , 1–23
		(2020).
597	45	
598	45.	Raj, D. <i>et al.</i> Switchable CAR-T cells mediate remission in metastatic pancreatic ductal
599		adenocarcinoma. <i>Gut</i> 68 , 1052–1064 (2019).
600	46.	Raj, D. et al. CEACAM7 is an effective target for CAR T-cell therapy of pancreatic
601		ductal adenocarcinoma. Clinical Cancer Research 27, 1538–1552 (2021).
602	47.	Sivapalan, L. et al. Longitudinal profiling of circulating tumour DNA for tracking
603		tumour dynamics in pancreatic cancer. <i>BMC Cancer</i> 22 , 1–17 (2022).
604	48.	Kocher, H. M. et al. Phase I clinical trial repurposing all-trans retinoic acid as a stromal
605		targeting agent for pancreatic cancer. <i>Nat Commun</i> 11 , 4841 (2020).
606	49.	Zardab, M. et al. Differentiating Ductal Adenocarcinoma of the Pancreas from Benign
607		Conditions Using Routine Health Records: A Prospective Case-Control Study. Cancers
608		(Basel) 15 , (2023).
609	50.	Ang, A., Michaelides, A., Chelala, C., Ullah, D. & Kocher, H. M. Prognostication for
610		recurrence patterns after curative resection for pancreatic ductal adenocarcinoma.
611		Ann Hepatobiliary Pancreat Surg 28 , 248–261 (2024).
612		
613		
614		
615		
616		
617		
618		
619		
620		
621		
622		
623		
624		

625 **Funding**

- 626 The PCRFTB is funded by PCRF. Organoid generation is supported by Barts Charity. HMK
- and CC acknowledge the support of NIHR Barts BRC. This work was supported by Barts
- 628 Charity (grant code MGU0504) and Barts NIHR BRC (grant code BTXH1A1R), part of the
- 629 Precision Medicine programme.
- 630

631 **Competing interests**

- 632 H.M.K. received a research grant for conducting this trial (Celgene: institutional) and
- educational grant support for attending or organizing conferences (Celgene, Baxalta, Mylan,
- 634 Medtronic, Oncosil: institutional) which are unrelated to this work. No other authors have
- 635 interests to declare.

636


637 Ethics approvals

- All tissue/sample donors provide written, informed consent, and all samples were collected,
- 639 processed and stored at each of the participating centres (Barts, Leicester, Swansea,
- 640 Oxford, Royal Free (London), Southampton, Newcastle, Plymouth, The London Clinic) under
- one Research Ethics Committee reference (13/SC/0593, renewed 18/SC/0629, renewed
- 642 23/SC/0282).

643

644 Author contributions

- 645 Conceptualization: CC; Methodology: JO, AZMDU, TSK, EG, GJT, MA; Software: JO;
- Validation: LS, HRA; Investigation: LS, HRA; Resources: PCRFTB, AI, AS, RR, CH; Data
- 647 Curation: MA, TSK, AZMDU, EG, JO, RR, CH; Writing original draft: LS; Writing Review
- 648 & Editing: HRA, HMK, CC; Supervision: CC; Funding acquisition: HMK, CC. All authors read
- 649 and approved the final manuscript.



D

Figure 1. Summary of available tissue types.

(A) The proportion of >3 400 unique organ site tissues available for study in the UK national Pancreatic Cancer Research Fund Tissue Bank, with the breakdown of controls (B) and pancreas (C) highlighted. (D) Distribution of >60 000 <u>PCRFTB</u> specimens by type, across all patients. Details are updated weekly. Additionally, radiological imaging is available for 171 patients with malignant, pre-malignant and benign pancreatic diagnoses, and >2,000 H&E images from 349 donors. Samples can be applied for <u>here</u>. (E) Geographical locations of PCRFTB patient recruitment sites.

Map created with <u>mapchart.net</u>. *=pancreatic juice, CTC, bile, organoids.




Figure 2. Advanced filtering options and clinical summaries for publicly available PDAC datasets. (A) Available data can be filtered according to various patient-related factors and tumour characteristics, including the stratification and analysis of cohorts according to KRAS and TP53 mutational status and established transcriptomic (TCGA, ICGC), genomic (ICGC) or histologically-derived AI (PacPaint) subtypes. (B) Dynamic bar charts allow multiple covariates to be viewed in relation to each other: e.g. survival trends in PDAC (TCGA) and neuroendocrine (ICGC PAEN-AU). (C, D, E) Each filtered attribute can be visualized as clinical summaries for each study cohort. Alternatively, data can be downloaded as .csv or .xls files, for offline analysis.




Figure 3. Transcriptomic stratification in PDAC reveals subtype-specific somatic variants

Oncoplots* of the top 25 most frequently mutated genes for consensus (A) n=27 *classical*-type and (B) n=16 *basal*-type PDAC cases (TCGA). (C) Overlap^ between the somatically mutated genes associated with best/worst prognosis subtypes across TCGA and ICGC PACA-AU cohorts combined. Genes highlighted in **bold** contain Tier 1 predicted oncogenic driver variants that have associated pharmacological inhibitors or chemotherapies (see Supplementary Table S1).

*Mutated genes are ranked in order of the *total* number of *mutations* in each given gene (where genes may have >1 mutation present; black 'multi-hit'), while the percentage to the right of each bar reflects the proportion of *samples* altered in the cohort. ^Created in <u>Venny 2.1</u>.





Figure 4. Differentially expressed genes between classical/progenitor and basal-like/QM/squamous TCGA PDAC tumours.

Box plots showing the trends of **(A)** TP53 and **(B)** MUC16 mRNA expression levels across all patients in each filtered TCGA PDAC group; best prognosis (n=27; classical/progenitor; left) and worst prognosis (n=16; basal/squamous/QM; right). **C**. Kaplan-Meier curve showing elevated MUC16 expression significantly associated with lower patient survival over 3 years, from n=402 PACA-AU PDAC patients with expression and outcome data (logrank p=0.011; hazard ratio (HR)=2.23). **D**. No association between MUC16 mRNA expression levels and outcome were observed in n=65 neuroendocrine carcinomas (PAEN-AU).






Figure 5. Frequently altered genes and biological pathways amongst n=756 *KRAS* wild-type PDAC tumours from GENIE

(A) Oncoplot showing the top 10 most frequently mutated genes in *KRAS* wild-type PDAC tumours (confirmed somatic missense mutations filtered out; insertions or duplications may still be present). (B) Alluvial plot showing gene targets harbouring any variants with therapeutic biomarker potential in \geq 5% of patients, as identified by the Cancer Genome Interpreter and based on data from <u>OncoKB</u>, <u>CIVic</u> (Clinical Interpretation of Variants in Cancer) and the <u>Cancer Biomarkers database</u>. (C) Altered biological pathways amongst *KRAS* wild-type PDAC tumours include MAPK and p53 signalling, as derived from the KEGG pathway database. The proportion of genes mutated in each pathway (left) and the proportion of all KRAS wild-type patients affected (x-axis) are given.